Page last updated: 2024-11-05

tranexamic acid and Angiohemophilia

tranexamic acid has been researched along with Angiohemophilia in 42 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Research Excerpts

ExcerptRelevanceReference
"These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease."9.69Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023)
"Tranexamic acid reduces blood loss in patients with bleeding diatheses and is used in a number of gynaecologic and non-gynaecologic conditions CASE: We discuss the case of a 27-year-old woman with type 1 von Willebrand disease, who presented with a two-year history of severe mittelschmerz secondary to recurrent hemorrhagic cysts."7.96Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts. ( Balayla, J; Gil, Y; Lasry, A, 2020)
"To study the prophylactic effects of tranexamic acid (TXA) for reduction of bleeding episodes in patients with VWD and GT in non-invasive conditions."7.83Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial. ( Bagheri, B; Eghbali, A; Melikof, L; Taherahmadi, H, 2016)
"Four cases of menorrhagia in von Willebrand disease were successfully treated with tranexamic acid given in a single daily dose of 4 g for the first 3-5 days of the menstrual cycle."7.70Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. ( Hull, DR; Mayne, EE; Ong, YL, 1998)
"These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease."5.69Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023)
" Prophylaxis (Desmopressin, clotting factor concentrates or tranexamic acid) to prevent bleeding was described in 100% (30/30) of EA procedures and in 4% (24/661) of hysterectomies."5.41Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review. ( Bongers, MY; Eising, HP; Leemans, JC; Punt, MC, 2023)
" Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia."5.31High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. ( Mohri, H, 2002)
" The highest-quality evidence is for the use of tranexamic acid in postpartum hemorrhage, which has been shown to decrease bleeding-related mortality in women without bleeding disorders."4.98Inherited Bleeding Disorders in the Obstetric Patient. ( Bannow, BS; Konkle, BA, 2018)
"8%) had menorrhagia, for which combined oral contraceptives, tranexamic acid and desmopressin were the most common first-line therapies for menorrhagia, whereas VWF was third-line therapy reported in 13 women (1."4.93Von Willebrand factor for menorrhagia: a survey and literature review. ( Brambilla, DJ; James, AH; Kessler, CM; Konkle, BA; Kouides, PA; Machin, N; Malec, LM; Neff, AT; Philipp, CS; Ragni, MV, 2016)
"Tranexamic acid reduces blood loss in patients with bleeding diatheses and is used in a number of gynaecologic and non-gynaecologic conditions CASE: We discuss the case of a 27-year-old woman with type 1 von Willebrand disease, who presented with a two-year history of severe mittelschmerz secondary to recurrent hemorrhagic cysts."3.96Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts. ( Balayla, J; Gil, Y; Lasry, A, 2020)
"To study the prophylactic effects of tranexamic acid (TXA) for reduction of bleeding episodes in patients with VWD and GT in non-invasive conditions."3.83Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial. ( Bagheri, B; Eghbali, A; Melikof, L; Taherahmadi, H, 2016)
"Four cases of menorrhagia in von Willebrand disease were successfully treated with tranexamic acid given in a single daily dose of 4 g for the first 3-5 days of the menstrual cycle."3.70Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. ( Hull, DR; Mayne, EE; Ong, YL, 1998)
"The most common form of BDs is von Willebrand Disease, reflecting 13% of adolescents with AUB."2.58Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders. ( Deligeoroglou, E; Karountzos, V, 2018)
"In vWD, the treatment of menorrhagia is usually medical, but there is lack of prospective data on the efficacy of commonly used medical therapies in these women."2.43Women and von Willebrand disease: controversies in diagnosis and management. ( Chi, C; Kadir, RA, 2006)
"Tranexamic acid was usually added for mucosal surgery."2.41Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. ( Griffioen, A; Harrington, C; Lee, CA; Nitu-Whalley, IC, 2001)
"Peri-procedural management of von Willebrand disease (VWD) utilizes von Willebrand factor (VWF) concentrates or desmopressin (DDAVP) to increase VWF levels."1.91Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes. ( Chandrakumaran, P; Hews-Girard, J; Poon, MC, 2023)
"Our review of the literature and the results of the survey showed considerable heterogeneity in treatment regimens, and a lack of consistency in reporting of the variables that determine factor concentrate dosing and monitoring."1.43Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey. ( Altisent, C; Dolan, G; Katsarou, O; López Fernández, MF; Windyga, J; Zülfikar, B, 2016)
"We have analyzed the databases for von Willebrand disease (VWD) from the hemophilia center for adult patients with bleeding disorders in South Australia."1.37Diagnosis and management of adult patients with von Willebrand disease in South Australia. ( Duncan, EM; Lloyd, JV; Mangos, HM; McRae, SJ; Rodgers, SE, 2011)
"Hemophilia A and B and von Willebrand disease (VWD) belong to the most frequent congenital coagulation disorders and are a significant problem in patients who require periodontal therapy or tooth extraction."1.36Comprehensive treatment of periodontitis in patients with von Willebrand disease. ( Alesci, S; Eickholz, P; Miesbach, W; Nickles, K; Wohlfeil, M, 2010)
" Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia."1.31High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. ( Mohri, H, 2002)
"A 42-year-old female with von Willebrand's disease was managed with desmopressin and tranexamic acid to aid haemostasis following a vaginal hysterectomy."1.31Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease. ( Bertholini, DM; Butler, CS, 2000)
"A patient with von Willebrand's disease had recurrent gastrointestinal bleeding from angiodysplasia, with inadequate response to von Willebrand factor substitution, medical and endoscopic treatment, and resection of affected bowel."1.31Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. ( Meijer, K; Peters, FT; van der Meer, J, 2001)

Research

Studies (42)

TimeframeStudies, this research(%)All Research%
pre-19903 (7.14)18.7374
1990's6 (14.29)18.2507
2000's11 (26.19)29.6817
2010's16 (38.10)24.3611
2020's6 (14.29)2.80

Authors

AuthorsStudies
Brignardello-Petersen, R2
El Alayli, A2
Husainat, N2
Kalot, M1
Shahid, S2
Aljabirii, Y2
Britt, A2
Alturkmani, H2
El-Khechen, H2
Motaghi, S2
Roller, J2
Dimassi, A1
Abughanimeh, O1
Madoukh, B1
Arapshian, A1
Grow, JM1
Kouides, P3
Laffan, M1
Leebeek, FWG1
O'Brien, SH1
Tosetto, A2
James, PD2
Connell, NT2
Flood, V1
Mustafa, RA2
Kalot, MA1
Abdul-Kadir, R1
Couper, S1
Lavin, M3
Ozelo, MC1
Weyand, A1
Flood, VH1
Chandrakumaran, P1
Hews-Girard, J1
Poon, MC1
Ragni, MV2
Rothenberger, SD1
Feldman, R1
Nance, D1
Leavitt, AD1
Malec, L1
Kulkarni, R1
Sidonio, R1
Kraut, E1
Lasky, J1
Pruthi, R1
Angelini, D1
Philipp, C1
Hwang, N1
Wheeler, AP1
Seaman, C1
Machin, N2
Xavier, F1
Meyer, M1
Bellissimo, D1
Humphreys, G1
Smith, KJ1
Merricks, EP1
Nichols, TC1
Ivanco, D1
Vehec, D1
Koerbel, G1
Althouse, AD1
Eising, HP1
Punt, MC1
Leemans, JC1
Bongers, MY1
Lasry, A1
Gil, Y1
Balayla, J1
Scott, M1
Hay, CRM1
Elkhalifa, S1
Tower, C1
Cocker, M1
Thachil, J1
Deligeoroglou, E1
Karountzos, V1
Lewandowski, B1
Wojnar, J1
Brodowski, R1
Mucha, M1
Czenczek-Lewandowska, E1
Brzęcka, D1
Bannow, BS1
Konkle, BA2
Tiede, A2
van Galen, KP1
Engelen, ET1
Mauser-Bunschoten, EP1
van Es, RJ1
Schutgens, RE1
Malec, LM1
James, AH1
Kessler, CM1
Kouides, PA1
Neff, AT1
Philipp, CS1
Brambilla, DJ1
Appelmann, I1
Kreher, S1
Parmentier, S1
Wolf, HH1
Bisping, G1
Kirschner, M1
Bergmann, F1
Schilling, K1
Brümmendorf, TH1
Petrides, PE1
Matzdorff, A1
Griesshammer, M1
Riess, H1
Koschmieder, S1
Windyga, J1
Dolan, G1
Altisent, C1
Katsarou, O1
López Fernández, MF1
Zülfikar, B1
Eghbali, A1
Melikof, L1
Taherahmadi, H1
Bagheri, B1
Sánchez-Luceros, A1
Woods, AI1
Bermejo, E1
Shukla, S1
Acharya, S1
Rydz, N1
Othman, M1
O'Donnell, JS1
Nickles, K1
Wohlfeil, M1
Alesci, S1
Miesbach, W1
Eickholz, P1
Mikhail, S1
Rodgers, SE1
Lloyd, JV1
Mangos, HM1
Duncan, EM1
McRae, SJ1
Nair, SC1
Viswabandya, A1
Srivastava, A2
Jiménez-Yuste, V1
Prim, MP1
De Diego, JI1
Villar, A1
Quintana, M1
Rabanal, I1
Sastre, N1
Hernández-Navarro, F1
Mohri, H1
Mannucci, PM2
Morimoto, Y1
Yoshioka, A1
Sugimoto, M1
Imai, Y1
Kirita, T1
Kadir, RA1
Chi, C1
Castaman, G1
Rodeghiero, F1
Cappelletti, A1
Baudo, F1
Eikenboom, JC2
Federici, AB2
Lethagen, S1
Linari, S1
Lusher, J1
Nishino, M1
Petrini, P1
Ungerstedt, JS1
Jackson, N1
Hashim, ZA1
Zainal, NA1
Jamaluddin, N1
Prinsley, P1
Wood, M1
Lee, CA2
Ong, YL1
Hull, DR1
Mayne, EE1
Onundarson, PT1
Baerlocher, GM1
Leoncini-Franscini, L1
Wuillemin, WA1
Furlan, M1
Sacco, R1
Stabile, F1
Carpenedo, M1
Zingaro, E1
Bertholini, DM1
Butler, CS1
Nitu-Whalley, IC1
Griffioen, A1
Harrington, C1
Stubbs, M1
Lloyd, J1
Meijer, K1
Peters, FT1
van der Meer, J1
Nilsson, IM1
Mikaelsson, M1
Vilhardt, H1
Walter, H1
van der Meer, FJ1
Briët, E1
Pignanelli, M1
Rota, L1
Pignanelli, C1
Vinckier, F1
Vermylen, J1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study[NCT02606045]Phase 360 participants (Anticipated)Interventional2019-02-07Active, not recruiting
National Study of Moderate and Severe Von Willebrand Disease in the Netherlands[NCT00510042]1,100 participants (Anticipated)Observational2007-07-31Completed
Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458]265 participants (Actual)Observational2012-11-05Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Centralized Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

InterventionIU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)1.63

Centralized Factor VIII (FVIII) Antigen (FVIII:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

InterventionIU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)3.64

Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

InterventionIU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)2.43

Centralized Von Willebrand Factor (VWF) Propeptide Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

InterventionIU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)7.3

Centralized Von Willebrand Factor Antigen (VWF:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

InterventionIU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)1.29

Local Laboratory Tests for Type 3 Von Willebrand's Disease (VWD3) Diagnosis (Composite)

"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)

InterventionParticipants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)265

Number of Patients With Available Local Laboratory Test for Anti-Von Willebrand Factor (Anti-VWF) Antibodies

Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)

InterventionParticipants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)4

Patients Experiencing Allergic Reactions During Use of Von Willebrand Factor (VWF)-Containing Concentrates

Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)

InterventionParticipants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)41

Number of Participants With Previous Use of Blood Products

Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)

InterventionParticipants (Count of Participants)
Packed red cellsCryoprecipitatesFresh frozen plasmaPlatelet concentrates
Type 3 Von Willebrand's Disease (VWD3)24123101

Reviews

12 reviews available for tranexamic acid and Angiohemophilia

ArticleYear
Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature.
    Blood advances, 2022, 01-11, Volume: 6, Issue:1

    Topics: Factor VIII; Hemostasis; Humans; Tranexamic Acid; von Willebrand Diseases; von Willebrand Factor

2022
Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review.
    Blood reviews, 2023, Volume: 62

    Topics: Female; Hemorrhage; Humans; Menorrhagia; Prospective Studies; Tranexamic Acid; von Willebrand Diseas

2023
Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders.
    Best practice & research. Clinical obstetrics & gynaecology, 2018, Volume: 48

    Topics: Adolescent; Antifibrinolytic Agents; Contraceptives, Oral, Combined; Female; Humans; Menorrhagia; Me

2018
Inherited Bleeding Disorders in the Obstetric Patient.
    Transfusion medicine reviews, 2018, Volume: 32, Issue:4

    Topics: Blood Coagulation; Deamino Arginine Vasopressin; Female; Fibrinolytic Agents; Hematology; Hemophilia

2018
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    The Cochrane database of systematic reviews, 2015, Dec-24, Issue:12

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor IX; Factor VIII; Hemophilia

2015
Von Willebrand factor for menorrhagia: a survey and literature review.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2016, Volume: 22, Issue:3

    Topics: Antifibrinolytic Agents; Contraceptives, Oral; Databases, Factual; Deamino Arginine Vasopressin; Fem

2016
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis
    Annals of hematology, 2016, Volume: 95, Issue:5

    Topics: Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Blood Loss, Surgical; Blood Transf

2016
New treatment approaches to von Willebrand disease.
    Hematology. American Society of Hematology. Education Program, 2016, Dec-02, Volume: 2016, Issue:1

    Topics: Deamino Arginine Vasopressin; Hemorrhage; Humans; Tranexamic Acid; von Willebrand Diseases; von Will

2016
Diagnosis and management of von Willebrand disease: a developing country perspective.
    Seminars in thrombosis and hemostasis, 2011, Volume: 37, Issue:5

    Topics: Clinical Laboratory Techniques; Coagulants; Deamino Arginine Vasopressin; Developing Countries; Fact

2011
Treatment of von Willebrand's Disease.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo

2004
Treatment of von Willebrand's Disease.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo

2004
Treatment of von Willebrand's Disease.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo

2004
Treatment of von Willebrand's Disease.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo

2004
Women and von Willebrand disease: controversies in diagnosis and management.
    Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:6

    Topics: Adolescent; Adult; Antifibrinolytic Agents; Contraceptives, Oral, Synthetic; Deamino Arginine Vasopr

2006
Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease.
    American journal of hematology, 2001, Volume: 66, Issue:4

    Topics: Anesthesia, Obstetrical; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Deamino Ar

2001

Trials

2 trials available for tranexamic acid and Angiohemophilia

ArticleYear
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.
    The Lancet. Haematology, 2023, Volume: 10, Issue:8

    Topics: Adolescent; Adult; Cross-Over Studies; Female; Hemorrhage; Humans; Menorrhagia; Middle Aged; Tranexa

2023
Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2000, Volume: 6, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Deamino Arginine Vasopressin; D

2000

Other Studies

28 other studies available for tranexamic acid and Angiohemophilia

ArticleYear
Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
    Blood advances, 2022, 01-11, Volume: 6, Issue:1

    Topics: Female; Humans; Menorrhagia; Postpartum Hemorrhage; Pregnancy; Systematic Reviews as Topic; Tranexam

2022
Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2023, Volume: 29, Issue:4

    Topics: Adolescent; Adult; Deamino Arginine Vasopressin; Factor VIII; Hemorrhage; Humans; Retrospective Stud

2023
Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts.
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2020, Volume: 42, Issue:11

    Topics: Adult; Cysts; Female; Hemorrhage; Humans; Ovulation; Pain; Pelvic Pain; Tranexamic Acid; Treatment O

2020
Management of pregnancy in type 3 von Willebrand disease with alloantibodies.
    British journal of haematology, 2018, Volume: 182, Issue:3

    Topics: Adult; Disease Management; Factor VIIa; Female; Humans; Isoantibodies; Platelet Transfusion; Pregnan

2018
Dental extractions in patients with mild hemophilia A and hemophilia B and von Willebrand disease without clotting factor supplementation.
    Polish archives of internal medicine, 2018, 08-31, Volume: 128, Issue:7-8

    Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Disorders, Inherited; Dental Caries; Female; Hemop

2018
Diagnosis and treatment of acquired von Willebrand syndrome.
    Thrombosis research, 2012, Volume: 130 Suppl 2

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Child; Child, Preschool; Deamino Arginine V

2012
Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2016, Volume: 22, Issue:5

    Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Coagulants; Databases, Factual; Dose-Response Rel

2016
Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2016, Volume: 22, Issue:5

    Topics: Antifibrinolytic Agents; Child, Preschool; Controlled Before-After Studies; Double-Blind Method; Fem

2016
PT-VWD posing diagnostic and therapeutic challenges - small case series.
    Platelets, 2017, Volume: 28, Issue:5

    Topics: Adolescent; Child, Preschool; Deamino Arginine Vasopressin; Drug Therapy, Combination; Factor VIIa;

2017
Comprehensive treatment of periodontitis in patients with von Willebrand disease.
    Journal of periodontology, 2010, Volume: 81, Issue:10

    Topics: Adult; Aggregatibacter actinomycetemcomitans; Aggressive Periodontitis; Anti-Bacterial Agents; Chron

2010
von Willebrand disease in the pediatric and adolescent population.
    Journal of pediatric and adolescent gynecology, 2010, Volume: 23, Issue:6 Suppl

    Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Child; Contusions; Deamino Arginine Vasopres

2010
Diagnosis and management of adult patients with von Willebrand disease in South Australia.
    Seminars in thrombosis and hemostasis, 2011, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Databases, Factual; Deamino Arginine Vasopr

2011
Otolaryngologic surgery in children with von Willebrand disease.
    Archives of otolaryngology--head & neck surgery, 2002, Volume: 128, Issue:12

    Topics: Adenoidectomy; Adolescent; Antifibrinolytic Agents; Child; Child, Preschool; Deamino Arginine Vasopr

2002
High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease.
    Journal of thrombosis and thrombolysis, 2002, Volume: 14, Issue:3

    Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female;

2002
Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
    Oral diseases, 2005, Volume: 11, Issue:4

    Topics: Adolescent; Adult; Child; Deamino Arginine Vasopressin; Dental Care for Chronically Ill; Factor VIII

2005
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study.
    Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:10

    Topics: Adolescent; Adult; Aged; Case-Control Studies; Child; Child, Preschool; Deamino Arginine Vasopressin

2006
Puerperal acquired factor VIII inhibitor causing a von Willebrand-like syndrome in a patient with anti-DNA antibodies.
    Singapore medical journal, 1995, Volume: 36, Issue:2

    Topics: Adult; Antibodies, Antinuclear; Factor VIII; Female; Gingival Hemorrhage; Humans; Lupus Erythematosu

1995
Adenotonsillectomy in patients with inherited bleeding disorders.
    Clinical otolaryngology and allied sciences, 1993, Volume: 18, Issue:3

    Topics: Adenoidectomy; Blood Coagulation Disorders; Child; Child, Preschool; Deamino Arginine Vasopressin; F

1993
Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid.
    Haemophilia : the official journal of the World Federation of Hemophilia, 1998, Volume: 4, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Drug Administration Schedule; Fema

1998
Treatment of menorrhagia in von Willebrand's disease.
    Haemophilia : the official journal of the World Federation of Hemophilia, 1999, Volume: 5, Issue:1

    Topics: Adult; Antifibrinolytic Agents; Female; Humans; Menorrhagia; Tranexamic Acid; von Willebrand Disease

1999
[Patient with recurrent gastrointestinal hemorrhage in acquired von Willebrand disease].
    Therapeutische Umschau. Revue therapeutique, 1999, Volume: 56, Issue:9

    Topics: Autoantibodies; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Recurrence; Tranexamic Aci

1999
Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease.
    Anaesthesia and intensive care, 2000, Volume: 28, Issue:2

    Topics: Acute Disease; Adult; Deamino Arginine Vasopressin; Female; Hemostatics; Humans; Hyponatremia; Hyste

2000
A protocol for the dental management of von Willebrand's disease, haemophilia A and haemophilia B.
    Australian dental journal, 2001, Volume: 46, Issue:1

    Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Clinical Protocols; Deamino Arginine Vasopressin;

2001
Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2001, Volume: 12, Issue:3

    Topics: Angiodysplasia; Blood Transfusion; Combined Modality Therapy; Deamino Arginine Vasopressin; Estrogen

2001
DDAVP factor VIII concentrate and its properties in vivo and in vitro.
    Thrombosis research, 1979, Volume: 15, Issue:1-2

    Topics: Adolescent; Aged; Arginine Vasopressin; Blood Coagulation; Blood Donors; Child; Deamino Arginine Vas

1979
Acquired von Willebrand's disease due to excessive fibrinolysis.
    British journal of haematology, 1992, Volume: 81, Issue:4

    Topics: Blood Coagulation Disorders; Fibrinolysis; Hemorrhagic Disorders; Humans; Male; Middle Aged; Tranexa

1992
[Extractions in hemophilic patients. Control of hemostasis with DDAVP].
    Dental Cadmos, 1988, Oct-15, Volume: 56, Issue:15

    Topics: Adolescent; Adult; Child; Deamino Arginine Vasopressin; Dental Care for Disabled; Hemophilia A; Hemo

1988
Dental extractions in hemophilia: reflections on 10 years' experience.
    Oral surgery, oral medicine, and oral pathology, 1985, Volume: 59, Issue:1

    Topics: Aminocaproic Acid; Bandages; Cellulose, Oxidized; Dental Care for Disabled; Factor IX; Factor VIII;

1985